Steroid treatment causes deterioration of myocardial function in the -sarcoglycan-deficient mouse model for dilated cardiomyopathy
Authors:
Open Access
- 20 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 79 (4) , 652-661
Abstract
As oral corticosteroids have a beneficial effect on muscle strength in Duchenne muscular dystrophy, it has been suggested that they may also be a useful treatment in the pathologically related sarcoglycanopathies. The δ-sarcoglycan-deficient mouse (Sgcd-null) is a model for both limb girdle muscular dystrophy 2F (LGMD2F) and dilated cardiomyopathy. To study the effect of oral corticosteroids on cardiac function, we treated 8-week-old Sgcd-null mice with prednisolone (1.5 mg/kg body weight/day orally) for 8 weeks. In vivo cardiac function was assessed by pressure–volume loops using a conductance catheter. We found a well-compensated cardiomyopathy at baseline in Sgcd-null mice with decreased myocardial contractility, increased preload, and decreased afterload, maintaining a high cardiac output. Cardiac haemodynamics, surprisingly, did not improve in prednisolone-treated mice, but instead deteriorated with evidence of ventricular stiffening. On histology, after steroid treatment there was increased myocardial cell damage and increased myocardial fibrosis. Prednisolone led to a decompensation of cardiac haemodynamics in Sgcd-null mice and induced additional cardiac damage. On the basis of these findings, although mouse models may not completely replicate the human situation for LGMD2F, we conclude that careful cardiac monitoring is clearly indicated in patients on long-term corticosteroids.Keywords
This publication has 39 references indexed in Scilit:
- Consequences of Disrupting the Dystrophin-Sarcoglycan Complex in Cardiac and Skeletal MyopathyTrends in Cardiovascular Medicine, 2007
- Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx miceNeuromuscular Disorders, 2006
- Prevention of TNFα-associated myocardial dysfunction resulting from cardiopulmonary bypass and cardioplegic arrest by glucocorticoid treatmentEuropean Journal of Cardio-Thoracic Surgery, 2006
- Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2–4 April 2004, Naarden, The NetherlandsNeuromuscular Disorders, 2004
- The Dystrophin Glycoprotein ComplexCirculation Research, 2004
- Dystrophin‐deficient cardiomyocytes are abnormally vulnerable to mechanical stress‐induced contractile failure and injuryThe FASEB Journal, 2001
- Evaluation of cardiac and respiratory involvement in sarcoglycanopathiesNeuromuscular Disorders, 2001
- Primary ?-sarcoglycan deficiency responsive to immunosuppression over three yearsMuscle & Nerve, 1998
- Mutations in the Sarcoglycan Genes in Patients with MyopathyNew England Journal of Medicine, 1997
- The Frequency of Familial Dilated Cardiomyopathy in a Series of Patients with Idiopathic Dilated CardiomyopathyNew England Journal of Medicine, 1992